Since agents that activate the ATM-mediated DNA damage response cause a similar splicing change (elevated CDC25C C5/C1) as the MDS-associated SRSF2 mutants, we wondered whether these point mutants may also activated the ATM-mediated DNA damage response. The gene discussed is SRSF2; the disease is myelodysplastic syndrome.